Navigation Links
Oncothyreon announces prioritization plan for development programs
Date:9/2/2008

SEATTLE, Sept. 2 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY) (TSX: ONY) (the "Company") today announced a prioritization plan to focus the Company's resources on the clinical development of PX-478 and PX-866 and on process development and manufacturing of Stimuvax(R). Oncothyreon will seek a partner for further clinical development of PX-12 beyond the ongoing trials. The prioritization plan is intended to concentrate Oncothyreon's efforts and available resources on those programs with the potential for the greatest near-term value creation for the Company's stockholders.

"This prioritization plan and the planned financing we also announced today are intended to make it possible for us to advance both PX-478 and PX-866 to the next stage of clinical development," said Robert L. Kirkman, M.D., President and Chief Executive Officer of Oncothyreon. "The ongoing dose escalation Phase 1 trial for PX-478, an inhibitor of hypoxia-inducible factor 1 alpha, is enrolling steadily and has not yet reached a maximum dose. The recently initiated Phase 1 trial for PX-866, an inhibitor of PI-3-kinase, is also enrolling well. We believe the high interest in the targets of these two compounds by both oncologists and potential partners will allow us to create value most effectively and quickly by concentrating our limited resources on these two programs. The next stage of development for PX-12 will require substantial resources and time, which would be more suitable in partnership with a larger pharmaceutical company."

"We will also continue our manufacturing and process development activities for Stimuvax," continued Dr. Kirkman. "The Phase 3 START trial of Stimuvax in non-small cell lung cancer is actively moving forward, and we expect an additional large Phase 3 trial in a new indication to be initiated later this year. To support these trials, we continue to manufacture significant quantities of Stimuvax for our partner, Merck KGaA of Darmstadt, Ger
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
2. Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
3. Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
4. Oncothyreon to receive milestone payment
5. Oncothyreon Reports First Quarter 2008 Financial Results
6. Oncothyreon files investigational new drug application for PX-866 oncology compound
7. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
8. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
9. Oncothyreon announces effectiveness of shelf registration statement
10. Oncothyreon announces issuance of patent for PX-867
11. Oncothyreon to present at upcoming investment conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... LAVAL, QC, June 4 /PRNewswire-FirstCall/ - Neptune Technologies & ... it has signed an agreement with Bayer Healthcare, LLC ... United States. , "The signing of this agreement with ... business and scientific choice to pursue the more demanding ...
... June 4 Santaris Pharma today announced that,the cancer ... by,Enzon Pharmaceuticals and Santaris Pharma A/S - was well ... treated cancer patients with,advanced malignancies. EZN-2968 is being evaluated ... which was presented at the 2009 American,Society of Clinical ...
... OPTR ) today announced that the Company will present at the following investor ... 8th Annual Needham Life Sciences Conference on Wednesday, June 10, ... New York City. , Jefferies, 3rd Annual ... the Mandarin Oriental Hotel in New York City. , ...
Cached Biology Technology:Neptune Products to be commercialized by BAYER HealthCare 2Neptune Products to be commercialized by BAYER HealthCare 3LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs of Clinical Benefit 2LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs of Clinical Benefit 3Optimer Pharmaceuticals to Present at June 2009 Investor Conferences 2
(Date:12/15/2014)... , Dec. 12, 2014 Research and ... the addition of the "Global Facial Recognition ... http://photos.prnewswire.com/prnh/20130307/600769 ... identification of individuals. Facial recognition system measures the ... nose, jaw edges, mouth, and the distance between ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... in wireless physiologic monitoring, has released a new ... changing needs of preclinical toxicology researchers. M series, ... to help toxicologists collect the best possible physiologic ... studies. Adding functional endpoints to toxicology ...
(Date:12/10/2014)... -- CIE San Diego has launched an innovative trust ... that enhances care coordination among social service and care ... earned a second $1 million grant from the Alliance ... in community and; will be recognized as a "Live ... 4-6p. CIE San Diego today announced the ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... of spinal cord injuries among senior citizens (age 70 and ... as compared with younger spinal cord injury patients, researchers at ... Center of the Delaware Valley recently reported. , As the ... 20 percent of its population will be older than age ...
... Systematic Review of the use of electronic mosquito repellents (EMRs) ... therefore say that there is no reason for recommending their ... to do more research with the devices. , Malaria is ... mosquito. Manufacturers of electronic mosquito repellents (EMRs) claim that the ...
... and zanamivir, are highly effective when given as ... the influenza virus, according to an analysis of ... Research Center, University of Michigan and University of ... the American Journal of Epidemiology. The analysis also ...
Cached Biology News:Elderly spinal cord injuries increase five-fold in 30 years, Jefferson neurosurgeons find 2Antivirals effectively curb influenza virus 2Antivirals effectively curb influenza virus 3
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Rabbit anti-NFkB p105/p50 (Ser337) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Biology Products: